🟢 SLS is trading 8.2% up today after Alliance Global raised its price target to $25

SLS is trading 8.2% higher at $14.61 following a significant price target increase from Alliance Global.

• Alliance Global raised its price target on Sellas Life Sciences to $25 from $10, significantly boosting sentiment for the small-cap biotech.
• The stock has experienced a volatile stretch with double-digit moves in both directions as investors await key Phase 3 trial results.
• The analyst action reflects growing optimism regarding the company's clinical pipeline and upcoming data milestones.